Search
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalIt is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. … HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.
E-2012
go.drugbank.com/drugs/DB05171ExperimentalE-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
Liotrix
go.drugbank.com/drugs/DB01583ApprovedLiotrix is a synthetically derived thyroid hormone replacement preparation. … It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues.
Romosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalRomosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921]. … Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924].
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalAcadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing … It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
Ciluprevir
go.drugbank.com/drugs/DB05868InvestigationalThe compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.
Monobenzone
go.drugbank.com/drugs/DB00600ApprovedWithdrawnMonobenzone is the monobenzyl ether of hydroquinone used medically for depigmentation. … Monobenzone occurs as a white, almost tasteless crystalline powder, soluble in alcohol and practically insoluble in water.
Enviomycin
go.drugbank.com/drugs/DB08993ExperimentalIt is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
Categories: Antiinfectives for Systemic UseXTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
3,4-Methylenedioxy-N-isopropylamphetamine
go.drugbank.com/drugs/DB06112ExperimentalHIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").